Grifols revenue and EBITDA growth, improved leverage ratio, and significant liquidity highlight its resilience and potential for future profitability. Learn more on GRFS stock here.

In this article, we are going to take a look at where Grifols, S.A. (NASDAQ ... term "defensive" a step further than practically any other industry. Improvements in medical technology, medications, ...

These samples are part of Grifols’ extensive plasma repository, which contains more than 100 million specimens collected over nearly 15 years. Their medical value is in their link to real-world ...

We recently compiled a list of the 12 Best Low Price Pharma Stocks To Invest In Right Now. In this article, we are going to take a look at where Grifols, S.A. (NASDAQ:GRFS) stands against the ...

Private equity company Brookfield has reportedly moved closer to taking control of Grifols, after months of disruption at the Spanish pharma company. A report in Spanish newspaper El Confidencial ...

Jorg Schuttrmpf, Chief Scientific Innovation Officer at Grifols, said in a recent interview with medical journal Drug Target Review, "Plasma, the liquid component of blood, holds vital clues about ...

Damaged muscles in ALS patients release proteins previously linked only to brain disease In a nutshell Researchers discovered ...

Grifols, S.A. (NASDAQ:GRFS) delivered strong financial results in Q3 2024, showing solid growth and improved financial health. Revenue reached EUR 1,793 million, reflecting a 12.4% year-over-year ...

The global HIV diagnostics market, valued at US$2.96B in 2024, is forecasted to grow at a 10.3% CAGR, reaching US$3.25B by ...

"This is not only because the symptoms are different from patient to patient, but because different patients have medical comorbidities ... Immunovant, Grifols, Amgen, Cabaletta Bio, Cour ...